ASX:CHM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ASX:CHM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Chimeric Therapeutics ASX:CHM +1.47% OCF Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Chimeric Therapeutics ranks worse than 62.36% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Chimeric Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was A$-3.84 Mil. Chimeric Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Chimeric Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.
As of today, Chimeric Therapeutics's current OCF Yield % is -238.07%.
The historical rank and industry rank for Chimeric Therapeutics's OCF Margin % or its related term are showing as below:
During the past 5 years, the highest OCF Margin % of Chimeric Therapeutics was -183.32%. The lowest was -183.32%. And the median was -183.32%.
The historical data trend for Chimeric Therapeutics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Chimeric Therapeutics Annual Data | |||||||||||
| Trend | Jun21 | Jun22 | Jun23 | Jun24 | Jun25 | ||||||
| OCF Margin % | 0.00 | 0.00 | 0.00 | 0.00 | -183.32 | ||||||
| Chimeric Therapeutics Semi-Annual Data | ||||||||||
| Jun21 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | Jun24 | Dec24 | Jun25 | Dec25 | |
| OCF Margin % | Get a 7-Day Free Trial |
|
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
For the Biotechnology subindustry, Chimeric Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Chimeric Therapeutics's OCF Margin % falls into.
OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.
Chimeric Therapeutics's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as
| OCF Margin | = | Cash Flow from Operations (A: Jun. 2025 ) | / | Revenue (A: Jun. 2025 ) |
| = | -7.276 | / | 3.969 | |
| = | -183.32 % |
Chimeric Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as
| OCF Margin | = | Cash Flow from Operations (Q: Dec. 2025 ) | / | Revenue (Q: Dec. 2025 ) |
| = | -3.841 | / | 0 | |
| = | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.